<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196897</url>
  </required_header>
  <id_info>
    <org_study_id>CT1000</org_study_id>
    <nct_id>NCT01196897</nct_id>
  </id_info>
  <brief_title>Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)</brief_title>
  <acronym>EVOLVE</acronym>
  <official_title>Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure
      Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2
      stroke risk stratification score of 1 or greater. This is a prospective, non-randomized study
      to evaluate the initial use of the next generation WATCHMAN Device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful implantation of the next generation WATCHMAN device without the occurance of life-threatening events caused by the device and/or procedure.</measure>
    <time_frame>12-Months</time_frame>
    <description>The implantation of the next generation WATCHMAN device without the occurrence of life-threatening events caused by the device and/or the procedure. These events may include device embolization requiring retrieval, bleeding events such as pericardial effusion requiring drainage, cardiac perforation requiring operation, cranial bleeding events due to any source, and any systemic embolic events related to the device or procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device Success</measure>
    <time_frame>Implant through 45-Days</time_frame>
    <description>Device success, defined as successful delivery and release of the WATCHMAN implant into the LAA, including successful re-capture and retrieval if necessary.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Implantable device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WATCHMAN LAA Closure Technology (Gen 4.0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WATCHMAN LAA Closure Technology (Gen 4.0)</intervention_name>
    <description>Implantation of the WATCHMAN device into the left atrial appendage.</description>
    <arm_group_label>Implantable device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Paroxysmal, persistent, or permanent non-valvular atrial fibrillation

          -  Eligible for long-term Warfarin therapy;

          -  Eligible to come off Warfarin therapy if the LAA is sealed

          -  Calculated CHADS2 score of 1 or greater

        Key Exclusion Criteria:

          -  New York Heart Association Class IV Congestive Heart Failure

          -  Recent MI (within 3 months)

          -  ASD and/or atrial septal repair or closure device

          -  Resting heart rate &gt;110 bpm

          -  Has an implanted mechanical valve prosthesis

          -  Left atrial appendage is obliterated

          -  Has undergone heart transplantation

          -  Has symptomatic carotid disease

          -  Contraindicated for aspirin

          -  LVEF &lt; 30%

          -  Cardiac Tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Na Homolce Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NA Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>150 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzige Bruder</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankt Katharinen Hospital / Cardiovasculares Centrum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>December 7, 2015</last_update_submitted>
  <last_update_submitted_qc>December 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Stroke</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Coumadin</keyword>
  <keyword>TIA</keyword>
  <keyword>Trans Ischemic Attack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

